MedTrace Logo

Efficacy Study in Allergic Rhinitis Patients After Intranasal Administration of AZD8848

NCT01185080 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 93

Last updated 2016-01-07

Study results available
· View outcomes & findings →

Summary

The primary purpose of this study is to investigate effect, tolerability and safety of different dosing regimens of AZD8848 administered intranasally to seasonal allergic rhinitis patients out of season in an allergen challenge model.

Conditions

  • Allergic Rhinitis

Interventions

DRUG

AZD8848

Nasal spray solution, intranasal, three times weekly for one month

DRUG

Placebo

Nasal spray solution, intranasal, three times weekly for one month

DRUG

AZD8848 and placebo

Nasal spray solution, intranasal, three times weekly for one month

Sponsors & Collaborators

Principal Investigators

  • Lennart Greiff, MD, PhD · Lund University Hospital, Sweden

  • Sam Lindgren, MD, PhD · AstraZeneca R&D Lund, Sweden

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-09-30
Primary Completion
2010-12-31
Completion
2012-01-31

Countries

  • Sweden

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01185080 on ClinicalTrials.gov